Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Caretek Medical announces re-brand as Glide Pharma and pipeline of own brand products


8 September 2006 -- Caretek Medical Ltd, a specialty pharmaceutical company developing products based on an innovative needle-free drug delivery system, has announced that it is changing its company name to Glide Pharmaceutical Technologies Ltd and will use the brand name of ‘Glide Pharma’ with immediate effect.

Oxford-based Glide PharmaTM is actively developing a pipeline of its own brand products, and co-developed products, based on its proprietary GlideTM technology which enables drugs, vaccines and other active pharmaceutical ingredients to be injected in a solid form. The company’s first product will be a needle-free injectable formulation of sumatriptan, a drug used to treat migraine attacks.

Most migraine sufferers currently take sumatriptan as an oral tablet or nasal spray. However, when faster and more reliable relief of the symptoms is required then the drug needs to be administered as an injection. At present, the only injectable version of sumatriptan, known as Imigran in the UK and Imitrex in the USA, is delivered via needle and syringe. With the clean and simple to use Glide technology, migraine sufferers will be able to administer a needle-free injection of a solid form sumatriptan product to obtain fast, reliable relief from their symptoms.

Dr Charles Potter, Founder and Chief Executive Officer of Glide Pharma, said: “We decided to re-brand as Glide Pharma because this name describes much more accurately what we do. We are now increasingly recognised as a specialty pharmaceutical company building a traditional pipeline of products based on our unique drug delivery system.”

Glide Pharma is currently establishing the manufacturing process for its injectable sumatriptan product and expects to start clinical trials in early 2007. The company is also exploring commercial opportunities for other drugs suitable for internal development and is undertaking feasibility studies with pharmaceutical partners to evaluate the Glide technology for the delivery of their proprietary drugs. Glide Pharma is also in discussion with a number of potential pharmaceutical partners who are interested in initiating feasibility studies to evaluate the administration of their drugs or vaccines with the Glide technology with a view to entering full co-development relationships.

Commenting on product development plans, Dr Potter said: “We plan to create a pipeline of our own brand Glide Pharma products as well as co-developing novel products with pharmaceutical partners. The ability to inject drugs in a solid form offers pharmaceutical companies a valuable new option for drug delivery, as it provides a stable, controllable and clean mechanism to deliver a wide range of drugs and vaccines either in the clinic or in the home environment.”

“Glide Pharma has the capability to formulate the proprietary drug of a partner into a new solid dosage form that is suitable for injection with the needle-free Glide technology - effectively providing a large pharmaceutical company with a new product. Or a partner might wish to use the Glide technology for a new drug that they are developing which requires a better delivery system than the conventional needle and syringe for administration of the drug at home.”

The reusable, handheld, Glide actuator device uses a spring mechanism to push solid drugs through the skin into the underlying tissue where they dissolve and are released into the patient’s bloodstream. In trials, volunteers have stated that they preferred injections with the Glide technology, rather than with a needle and syringe, praising the speed of the Glide injection process and the simple, easy to use nature of the actuator device.

GPs have also endorsed the Glide technology as a user-friendly, effective delivery system that is particularly suitable for home use by patients or carers and does not carry the hazards of disposal and needle prick injuries associated with syringes and needles. The drug cass


Publisher Contact Information:

Glide Pharma (formerly Caretek Medical Ltd.)
+44 (0)1865 811199
m.henry@oxin.co.uk

Company profile of Glide Pharmaceutical Technologies Ltd (formerly Caretek Medical Ltd.)
Past press releases of Glide Pharmaceutical Technologies Ltd (formerly Caretek Medical Ltd.).

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.